Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma

Mithat Gonen; Kaitlyn Redling; Nikoletta Lendvai; Hani Hassoun; Heather Landau; David J Chung; Guenther Koehne; Minal Patel; Kristina W. Brennan; Kai Wang; Eric M Sanford; Tim Brennan; Geoff A. Otto; Michelle K. Nahas; Doron Lipson; Philip J. Stephens; Roman Yelensky; Vincent A. Miller; Marcel Van Den Brink; Ross L. Levine; Ahmet Dogan; Sergio A Giralt

Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma

Mithat Gonen, Kaitlyn Redling, Nikoletta Lendvai, Hani Hassoun, Heather Landau, David J Chung, Guenther Koehne, Minal Patel, Kristina W. Brennan, Kai Wang, Eric M Sanford, Tim Brennan, Geoff A. Otto, Michelle K. Nahas, Doron Lipson, Philip J. Stephens, Roman Yelensky, Vincent A. Miller, Marcel Van Den Brink, Ross L. LevineAhmet Dogan, Sergio A Giralt

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	122
State	Published - Nov 15 2013

Disciplines

Medicine and Health Sciences
Oncology
Genetics
Immunology and Infectious Disease

Cite this

Gonen, M., Redling, K., Lendvai, N., Hassoun, H., Landau, H., Chung, D. J., Koehne, G., Patel, M., Brennan, K. W., Wang, K., Sanford, E. M., Brennan, T., Otto, G. A., Nahas, M. K., Lipson, D., Stephens, P. J., Yelensky, R., Miller, V. A., Van Den Brink, M., ... Giralt, S. A. (2013). Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. Blood, 122.

Gonen, M, Redling, K, Lendvai, N, Hassoun, H, Landau, H, Chung, DJ, Koehne, G, Patel, M, Brennan, KW, Wang, K, Sanford, EM, Brennan, T, Otto, GA, Nahas, MK, Lipson, D, Stephens, PJ, Yelensky, R, Miller, VA, Van Den Brink, M, Levine, RL, Dogan, A & Giralt, SA 2013, 'Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma', Blood, vol. 122.

@article{c20ece432b234fcbbb1b404000120960,

title = "Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma",

author = "Mithat Gonen and Kaitlyn Redling and Nikoletta Lendvai and Hani Hassoun and Heather Landau and Chung, \{David J\} and Guenther Koehne and Minal Patel and Brennan, \{Kristina W.\} and Kai Wang and Sanford, \{Eric M\} and Tim Brennan and Otto, \{Geoff A.\} and Nahas, \{Michelle K.\} and Doron Lipson and Stephens, \{Philip J.\} and Roman Yelensky and Miller, \{Vincent A.\} and \{Van Den Brink\}, Marcel and Levine, \{Ross L.\} and Ahmet Dogan and Giralt, \{Sergio A\}",

note = "Background Patients with multiple myeloma (MM) have realized improved survival with the development of multi-drug combinations using immunomodulatory drugs (IMiDs), proteasome inhibitors, and alkylating agents. Nevertheless, all MM patients eventually become refractory to available therapies, underscoring the importance of identifying additional rational therapeutic targets.",

year = "2013",

month = nov,

day = "15",

language = "American English",

volume = "122",

journal = "Blood",

}

TY - JOUR

T1 - Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma

AU - Gonen, Mithat

AU - Redling, Kaitlyn

AU - Lendvai, Nikoletta

AU - Hassoun, Hani

AU - Landau, Heather

AU - Chung, David J

AU - Koehne, Guenther

AU - Patel, Minal

AU - Brennan, Kristina W.

AU - Wang, Kai

AU - Sanford, Eric M

AU - Brennan, Tim

AU - Otto, Geoff A.

AU - Nahas, Michelle K.

AU - Lipson, Doron

AU - Stephens, Philip J.

AU - Yelensky, Roman

AU - Miller, Vincent A.

AU - Van Den Brink, Marcel

AU - Levine, Ross L.

AU - Dogan, Ahmet

AU - Giralt, Sergio A

N1 - Background Patients with multiple myeloma (MM) have realized improved survival with the development of multi-drug combinations using immunomodulatory drugs (IMiDs), proteasome inhibitors, and alkylating agents. Nevertheless, all MM patients eventually become refractory to available therapies, underscoring the importance of identifying additional rational therapeutic targets.

PY - 2013/11/15

Y1 - 2013/11/15

UR - http://www.bloodjournal.org/content/122/21/755?sso-checked=true

M3 - Article

VL - 122

JO - Blood

JF - Blood

ER -

Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma

Disciplines

Other files and links

Cite this